F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comVaishali Pharma Ltd is a small-cap pharmaceutical company primarily engaged in the trading and export of active pharmaceutical ingredients (APIs), intermediates, and formulations. The company operates in a sector that benefits from long-term healthcare demand, export opportunities, and India’s growing role as a global pharma supplier.
Although Vaishali Pharma is a micro-cap stock with high volatility, it has shown periods of strong price momentum in the past. In this article, we analyze Vaishali Pharma Ltd share price targets from 2026 to 2030 based on current market data, business fundamentals, shareholding pattern, and long-term pharma sector outlook.
| Detail | Value |
|---|---|
| Open | ₹8.10 |
| Previous Close | ₹7.87 |
| Day’s High | ₹8.10 |
| Day’s Low | ₹7.80 |
| VWAP | ₹7.88 |
| 52-Week High | ₹18.80 |
| 52-Week Low | ₹7.40 |
| All-Time High | ₹24.91 |
| All-Time Low | ₹2.42 |
| Market Capitalization | ₹103 Cr |
| Volume | 43,857 |
| Value (Lacs) | ₹3.47 |
| 20D Avg Volume | 1,85,402 |
| 20D Avg Delivery (%) | 58.37% |
| Face Value | ₹2 |
| Book Value Per Share | ₹5.16 |
| Beta | 0.00 |
| UC Limit | ₹9.44 |
| LC Limit | ₹6.30 |
Vaishali Pharma Ltd is involved in:
Export and trading of APIs and intermediates
Supply of pharmaceutical formulations
International pharma distribution
The company largely operates on an asset-light business model, focusing on sourcing, compliance, and export relationships rather than heavy manufacturing. This allows scalability but also makes margins sensitive to pricing and volumes.
Exposure to global pharmaceutical export markets
Asset-light model with lower capex requirements
High delivery percentage indicating long-term holding interest
Pharma sector offers defensive characteristics over long periods
Small market cap allows scope for sharp re-rating if growth improves
Global demand for generic medicines continues to rise
India remains a preferred sourcing hub for APIs and formulations
Export-focused pharma companies benefit from currency tailwinds
Micro-cap pharma stocks are volatile but can outperform during sector upcycles
| Investor Category | Holding (%) |
|---|---|
| Retail & Others | 68.39% |
| Promoters | 31.61% |
The company has moderate promoter holding, while the majority stake lies with retail investors, indicating higher volatility and speculative interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 14 | 18 |
| 2027 | 20 | 26 |
| 2028 | 28 | 36 |
| 2029 | 40 | 50 |
| 2030 | 55 | 70 |
These targets assume improvement in business scale, better revenue consistency, and favorable pharma export conditions.
By 2026, better volume growth and export demand could support initial recovery.
Growth Drivers
Increased export orders
Improved working capital cycle
Better utilization of trading opportunities
Investment View
High-risk, suitable only for small allocation.
In 2027, earnings stability may lead to valuation expansion.
Growth Drivers
Broader product portfolio
Stronger overseas customer base
Improving revenue visibility
Investment View
Speculative but attractive for patient investors.
By 2028, consistent execution could result in market re-rating.
Growth Drivers
Scaling of pharma exports
Improved margins
Higher investor confidence
Investment View
High-risk, high-reward micro-cap opportunity.
With sustained growth, the stock may show strong momentum.
Growth Drivers
Stable global pharma demand
Currency benefits on exports
Better cost efficiency
Investment View
Favors investors holding through volatility.
By 2030, Vaishali Pharma could emerge as a stronger export-focused pharma player.
Growth Drivers
Long-term healthcare demand
Improved scale and credibility
Re-rating of profitable micro-cap pharma stocks
Investment View
Suitable only for investors with very high risk tolerance.
Vaishali Pharma Ltd is a high-risk micro-cap pharmaceutical stock. While the pharma sector offers long-term growth potential, the company’s small size, limited institutional holding, and volatile earnings make it suitable only for speculative or high-risk portfolios.
Pharma export growth potential
Low absolute stock price
High delivery percentage
Possibility of sharp re-rating
Very small market capitalization
Low promoter holding
Earnings volatility
Liquidity and governance risks common to micro-caps
Regular monitoring of financial results is critical.
Vaishali Pharma Ltd offers long-term optionality with high risk. If execution improves and pharma exports scale meaningfully, the stock could deliver substantial returns from current levels. Based on assumptions of gradual improvement, the share price could range between ₹55 and ₹70 by 2030.
This stock is best suited for investors who understand micro-cap risks and can tolerate sharp volatility.
1. What is the current share price of Vaishali Pharma Ltd?
It is around ₹7.8–₹8.1 as per the latest provided data.
2. What is the share price target for 2026?
The estimated range is ₹14 to ₹18.
3. Is Vaishali Pharma Ltd a good long-term investment?
Only for high-risk investors comfortable with micro-cap volatility.
4. What is the share price target for 2030?
The projected range is ₹55 to ₹70.
5. What factors influence the stock price most?
Export growth, profitability, working capital management, and overall pharma sector sentiment.
Disclaimer: This article is for educational purposes only and not investment advice. Please consult a certified financial advisor before making any investment decisions.
Register & Login